Cargando…
Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin's Lymphoma including Waldenström's macroglobulinemia (WM). Ibrutinib, acala...
Autores principales: | Bou Zerdan, Maroun, Valent, Jason, Diacovo, Maria Julia, Theil, Karl, Chaulagain, Chakra P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791721/ https://www.ncbi.nlm.nih.gov/pubmed/35096069 http://dx.doi.org/10.1155/2022/1182384 |
Ejemplares similares
-
Multidisciplinary supportive care in systemic light chain amyloidosis
por: Maroun, Bou Zerdan, et al.
Publicado: (2022) -
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022) -
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022) -
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023) -
Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia)
por: Ho, Vivian V., et al.
Publicado: (2022)